2007-09-30-世界卫生组织-WHO_HPV_LabNet_-_Newsletter_01_6页_594kb

Summary of WHO HPV LabNet Newsletter, 1 October 2007

Background and Purpose

The WHO HPV LabNet was established in response to advances in HPV vaccine development to harmonize laboratory assays. Its mission is to improve the quality of laboratory services for effective surveillance and monitoring of HPV vaccination impact through enhanced, state-of-the-art support, including standardized procedures, quality assurance, training, and a network for surveillance. It aims to speed up HPV vaccine implementation by facilitating validated labs, developing capacity, and providing up-to-date technical information.

Structure

The LabNet operates at three voluntary levels: Global Reference Laboratories, Regional Laboratories, and National/Local Laboratories, subject to independent WHO review. Global reference labs handle confirmatory testing, while regional and national labs focus on local implementation.

Participating Laboratories (September 2007)

• Global Reference Laboratories:
  • Europe: Professor Joakim Dillner.
  • USA: Dr. Elizabeth Unger.
  • Western Pacific: Professor Suzanne Garland.
  • South-East Asia: Professor Bhudev C. Das and Dr. Sukhon Sukvirach.
  • Africa: Professor Anna-Lise Williamson.
  • WHO Collaborating Centre for Biological Standards: Dr. Morag Ferguson and Dr. Dianna Wilkinson.
• Regional Laboratories:
  • Eastern Mediterranean: Not specified in the text.
  • Europe: Also referenced under global, but specific to Europe.
  • Western Pacific: Covered under global collaboration.
  • South-East Asia: Covered under global.
  • Africa: Professor Anna-Lise Williamson.

Establishment of International Standards for HPV Detection

Two major international collaborative studies were conducted to standardize HPV detection:

• HPV Antibody Detection (First Study): Compared 10 laboratories worldwide. Found significant inter-laboratory variation in antibody titres and demonstrated that a standardized HPV16 antibody sample improved comparability. Concluded that establishing an International Standard for HPV16 antibodies would facilitate global consistency using International Units.
• HPV DNA Detection (Second Study): Involved 29 laboratories. Most accurately detected HPV types at high concentrations, with no compromise in HPV16/18 detection with other high-risk types. Recommended using recombinant HPV DNA for standards, with focus on HPV16/18 and sensitivity needs in different settings.

Recent/Upcoming Meetings

• June 2007 Workshop and Practical Course: First Global HPV LabNet meeting at Institut de Microbiology, CHUV, Lausanne, Switzerland. Aimed to review progress, promote LabNet, and provide training in DNA genotyping, HPV16/18 serology, and proficiency panel use. Outcomes included drafting WHO Laboratory Manual for HPV diagnosis and defining communication strategy.
• September 2007 HEAG Meeting: HPV experts reviewed evidence for HPV vaccine recommendations, high-priority research, and decision-making support for HPV-related disease prevention in WHO Member States.
• November 2007 Informal Meeting: To update the network at the 24th International Papillomavirus Conference in Beijing.

Ongoing Projects

• Development of International Standard for anti-HPV type 16 antibody, to be reviewed by WHO ECBS in October 2007.
• WHO Collaborative Study for HPV16/18 DNA standards, data review by November 2007.
• Development of the Global HPV Laboratory Manual, with 1st draft in progress and external expert consultation planned for January 2008.
• Preparation of a Proficiency Panel for HPV DNA Detection, currently in process.

Conclusion from Editorial Notes

The studies highlighted significant inter-laboratory variation in HPV antibody levels and DNA detection, underscoring the need for standardized operating procedures, quality control panels, and reference reagents. These should ensure consistency, long-term stability, availability, and mimicry of biological samples to advance HPV control efforts. Further details and resources are available through WHO links.